It is with a heavy heart that we announce the departure of Daniel F. Martin, MD, Chair of Cole Eye Institute, Barbara and A. Malachi Mixon III Institute Chair.
Since Dr. Martin’s appointment as Chairman in 2008, he guided the institute through a transformative period of exponential clinical and academic growth that led to Cole Eye consistently ranked as a top ophthalmology department. In 2008, Cole Eye comprised the main campus and 3 satellites. By 2024, Dr. Martin grew this footprint to include over 27 satellites, almost tripling the clinical volume to 400,000 annual visits and over 24,000 surgical cases. And with the generous support of Jeffrey and Patricia Cole, Dr. Martin led a 150,000 square foot expansion project in addition to the renovation of our existing 130,000 square foot building.
Dr. Martin has been a champion for research at Cole Eye that has tripled the number of NIH grants 5 to 15 R01/Department of Defense grants, in addition to an NIH P30 core grant, an NIH T32 training grant, a Research to Prevent Blindness (RPB) core grant and a Cleveland Eye Bank Foundation core grant. The number of clinical trials performed each year has increased from 15 to over 50.
Dr. Martin is also a pioneer in the field of ophthalmology, retinal disease and clinical trials. In his early career, he led efforts to improve treatment of CMV retinitis. This led to the approval of multiple revolutionary therapies, including the ganciclovir implant and oral val-ganciclovir. His advocacy for patients with HIV/AIDS led to increased funding for both research and treatments. He also led the Comparison of AMD Treatment Trial (CATT). His tiresome leadership in the design, implementation and funding of this trial led to billions of dollars in cost saving by Medicare. His advocacy to Congress led to changes at Center for Medicare and Medicaid Services (CMS) to allow for such trials in the future. He has been the chair of the DRCR Retina Network since 2018, an NIH sponsored national retina clinical trials network that includes over 150 centers and has completed 39 clinical trials to date.
Beyond clinical excellence and research, his commitment to education led to the expansion of our residency program with 5 residents per year. With the generous support of the Timken family, he also led efforts to create a world class wet lab for our ophthalmology trainees. His support of the education mission led to our ophthalmology residency to be ranked amongst the top 10 programs in the United States.
Dr. Martin will be returning to the faculty at the Emory University School of Medicine. Dr. Martin has left an indelible mark on ophthalmology and Cole Eye through his groundbreaking contributions and visionary leadership, and his impact will always be warmly remembered. Please join us on congratulating Dr. Martin on his many accomplishments and best wishes for the future!